Aerosol Inhalation Treatment for Dyspnea - Patients

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Dyspnea

In brief

The purpose of this protocol is to develop and test aerosol furosemide, as a treatment that has the potential to significantly improve symptom management and enhance the quality of care for patients with intractable dyspnea.

Key facts

Study ID

NCT02524054

Run by

Beth Israel Deaconess Medical Center

People needed

24

Starts

2014-11-01

Expected to finish

2017-12-01

Last updated by the study team

2018-01-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Intractable dyspnea at rest or with minimal activity

You may not qualify if…

• Chronic congestive heart failure
• Liver or kidney disease
• Systemic lupus erythematosis (SLE)
• Receiving potassium supplementation or other indication of hypokalemia
• Major psychiatric disorders
• Furosemide hypersensitivity
• Not mentally competent and/or alert (unable to grant informed consent)
• Under 18 years old
• Not fluent in English
• Inadequate birth control

Where it is running

• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.